BRPI0507462A - compostos de quinolina substituìdos - Google Patents

compostos de quinolina substituìdos

Info

Publication number
BRPI0507462A
BRPI0507462A BRPI0507462-2A BRPI0507462A BRPI0507462A BR PI0507462 A BRPI0507462 A BR PI0507462A BR PI0507462 A BRPI0507462 A BR PI0507462A BR PI0507462 A BRPI0507462 A BR PI0507462A
Authority
BR
Brazil
Prior art keywords
compounds
quinoline compounds
substituted quinoline
compositions
mtp
Prior art date
Application number
BRPI0507462-2A
Other languages
English (en)
Inventor
Peter Bertinato
Michel Andre Couturier
Ernest Seiichi Hamanaka
Marcus Douglas Ewing
Ralph Pelton Robinson Jr
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0507462A publication Critical patent/BRPI0507462A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

COMPOSTOS DE QUINOLINA SUBSTITUìDOS. A presente invenção refere-se aos inibidores de secreção MTP/Apo-B de fórmula (l) em que R¬ 1¬ -R¬ 7¬, X¬ 1¬, m e n são como definidos no relatório, assim como as composições farmacêuticas compreendendo os compostos, e métodos de uso dos compostos e composições. Os compostos da invenção são utilizá-veis no tratamento de obesidade e doenças, condições ou distúrbios associados.
BRPI0507462-2A 2004-02-04 2005-01-24 compostos de quinolina substituìdos BRPI0507462A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06
PCT/IB2005/000167 WO2005080373A1 (en) 2004-02-04 2005-01-24 Substituted quinoline compounds

Publications (1)

Publication Number Publication Date
BRPI0507462A true BRPI0507462A (pt) 2007-07-10

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507462-2A BRPI0507462A (pt) 2004-02-04 2005-01-24 compostos de quinolina substituìdos

Country Status (25)

Country Link
US (3) US7468378B2 (pt)
EP (1) EP1716137A1 (pt)
JP (1) JP2007520543A (pt)
KR (1) KR100799802B1 (pt)
AP (1) AP2006003685A0 (pt)
AR (1) AR047529A1 (pt)
AU (1) AU2005214159A1 (pt)
BR (1) BRPI0507462A (pt)
CA (1) CA2555133A1 (pt)
CO (1) CO5700721A2 (pt)
CR (1) CR8544A (pt)
EA (1) EA010369B1 (pt)
EC (1) ECSP066717A (pt)
GE (1) GEP20084360B (pt)
IL (2) IL176715A0 (pt)
MA (1) MA28347A1 (pt)
NL (1) NL1028192C2 (pt)
NO (1) NO20063928L (pt)
OA (1) OA13365A (pt)
PA (1) PA8623001A1 (pt)
PE (1) PE20050773A1 (pt)
SV (1) SV2007002007A (pt)
TW (2) TWI306454B (pt)
UY (1) UY28734A1 (pt)
WO (1) WO2005080373A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20070203139A1 (en) * 2004-04-14 2007-08-30 Astrazeneca Ab Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
NZ563009A (en) 2005-04-19 2011-05-27 Surface Logix Inc Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
ATE520651T1 (de) * 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
WO2008097471A1 (en) * 2007-02-02 2008-08-14 Shivvers Steve D High efficiency drier with multi stage heating and drying zones
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
CA2702984C (en) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2010018547A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. Aminoquinoline compounds
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
AP2013007331A0 (en) 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
ES2552989T3 (es) * 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP3107540A4 (en) * 2014-02-17 2017-08-30 Hetero Research Foundation Polymorphs of lomitapide and its salts
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
US10138206B2 (en) 2014-10-09 2018-11-27 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP6906105B2 (ja) * 2017-06-16 2021-07-21 成都先導薬物開発股▲ふん▼有限公司Ｈｉｔｇｅｎ Ｌｔｄ． Ｒｏｃｋを阻害する化合物及びその使用
IL272032B2 (en) 2017-07-17 2026-04-01 Vertex Pharma Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
NZ199968A (en) 1981-03-11 1985-10-11 Wellcome Found Benzoic acid derivatives and naphthoic acid derivatives and pharmaceutical compositions
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE69531458T2 (de) 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5919795A (en) 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
NZ332341A (en) * 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
CA2259431A1 (en) 1996-07-01 1998-01-08 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
WO1998027979A1 (en) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
EP1042295B1 (en) * 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
IL139449A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
NZ525591A (en) 2000-10-05 2004-04-30 Fujisawa Pharmaceutical Co Benzamide compounds as Apo B secretion inhibitors
BR0210616A (pt) 2001-06-28 2004-09-28 Pfizer Prod Inc Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
CZ2004634A3 (cs) * 2001-10-25 2004-10-13 Takedaáchemicaláindustriesźáltd Chinolinová sloučeninaŹ způsob výroby a použití a farmaceutický přípravek
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
US20030162788A1 (en) * 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
ZA200502496B (en) 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
EP1581499A1 (en) * 2002-12-20 2005-10-05 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
WO2004056777A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물

Also Published As

Publication number Publication date
NO20063928L (no) 2006-10-31
AP2006003685A0 (en) 2006-08-31
OA13365A (en) 2007-04-13
MA28347A1 (fr) 2006-12-01
AR047529A1 (es) 2006-01-25
NL1028192A1 (nl) 2005-08-08
NL1028192C2 (nl) 2006-05-30
CA2555133A1 (en) 2005-09-01
KR20060127123A (ko) 2006-12-11
UY28734A1 (es) 2005-09-30
US20060223851A1 (en) 2006-10-05
US20050234099A1 (en) 2005-10-20
CO5700721A2 (es) 2006-11-30
EA010369B1 (ru) 2008-08-29
SV2007002007A (es) 2007-03-20
US20070093525A1 (en) 2007-04-26
IL208963A0 (en) 2011-07-31
CR8544A (es) 2006-11-30
WO2005080373A1 (en) 2005-09-01
IL176715A0 (en) 2006-10-31
EA200601239A1 (ru) 2007-02-27
EP1716137A1 (en) 2006-11-02
KR100799802B1 (ko) 2008-01-31
TW200906800A (en) 2009-02-16
GEP20084360B (en) 2008-04-29
JP2007520543A (ja) 2007-07-26
AU2005214159A1 (en) 2005-09-01
PE20050773A1 (es) 2005-10-26
TWI306454B (en) 2009-02-21
TW200533354A (en) 2005-10-16
PA8623001A1 (es) 2006-03-24
US7468378B2 (en) 2008-12-23
US7393958B2 (en) 2008-07-01
ECSP066717A (es) 2006-10-31
US7368573B2 (en) 2008-05-06

Similar Documents

Publication Publication Date Title
NO20063928L (no) Substituerte kinolinforbindelser
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
BRPI0411721A (pt) derivados de tiazolilpiperidina como inibidores de mtp
BRPI0418102A (pt) derivados de quinolina
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
DE602006010564D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
BRPI0513901A (pt) derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
CY1109842T1 (el) Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.